榮昌生物：原研新型雙特異性抗體獲納入內地突破性治療藥物品種

　　《經濟通通訊社１９日專訊》榮昌生物（０９９９５）（滬：６８８３３１）宣布，公司原
研的新型雙特異性抗體ＲＣ１４８，被中國國家藥品監督管理局藥品審評中心（ＣＤＥ）正式納
入突破性治療藥物品種，針對適應症為ＲＣ１４８聯合多西他賽治療經ＰＤ－１╱ＰＤ－Ｌ１抑
制劑和含鉑化療（聯合或序貫）治療失敗的驅動基因陰性局部晚期或轉移性非小細胞肺癌
（ＮＳＣＬＣ）。（ｒｈ）

【你點睇？】美烏元首白宮會談後，特朗普再與普京通電，你認為美國能否促成「普澤會」？你對俄烏實現和平有多大信心？► 立即投票

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。